Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

Therapeutic drug monitoring, liquid biopsies or pharmacogenomics for prediction of human drug metabolism and response

Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine

Pharmaco-metabonomic phenotyping and personalized drug treatment

Individualized pharmacotherapy utilizing genetic biomarkers and novel in vitro systems as predictive tools for optimal drug development and treatment

[Personalized Dosing from Perspective of Pharmacogenomics of Drug Metabolizing Enzymes and Transporters].

Emerging therapeutic drug monitoring technologies: considerations and opportunities in precision medicine

Utility, promise, and limitations of liquid chromatography‐mass spectrometry‐based therapeutic drug monitoring in precision medicine

PHARMACOGENOMICS: Driving Personalized Medicine

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

Promises and challenges in pharmacoepigenetics

Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication

State-of-the-Art Technologies to Interrogate Genetic/Genomic Components of Drug Response

From Endogenous Compounds as Biomarkers to Plasma‐Derived Nanovesicles as Liquid Biopsy; Has the Golden Age of Translational Pharmacokinetics‐Absorption, Distribution, Metabolism, Excretion‐Drug–Drug Interaction Science Finally Arrived?

Application of New Cellular and Microphysiological Systems to Drug Metabolism Optimization and Their Positioning Respective to In Silico Tools

Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy

Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment

Strategies to Identify Pharmacogenomic Biomarkers: Candidate Gene, Pathway-Based, and Genome-Wide Approaches

Information of ADME-Associated Proteins and Potential Application for Pharmacogenetic Prediction of Drug Responses

Pharmacogenomics: current status and future perspectives

Pharmacometabolomics in Drug Disposition, Toxicity and Precision Medicine

Pharmacometabolomics-Based Translational Biomarkers: How to Navigate the Data Ocean